Plain-English translation of NCT05125055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining toripalimab (an immune-boosting drug) with chemotherapy can help shrink mouth cancers better than chemotherapy alone before surgery. You would receive two rounds of treatment about three weeks apart, then have surgery to remove the cancer. The goal is to see whether this newer approach helps more patients achieve a major shrinkage of their tumor.
Earlier research showed that this medication combined with chemotherapy shrank tumors in many patients with advanced mouth cancer and was well-tolerated. This larger trial aims to confirm whether this combination approach truly works better than the standard treatment currently used.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of two treatment plans. Both involve two rounds of intravenous chemotherapy given about three weeks apart at a hospital or clinic. One group also receives the new immune-boosting drug toripalimab alongside the chemotherapy. After completing the two rounds of treatment, you would have surgery to remove the cancer, followed by additional standard treatment as needed. The entire study period before surgery typically lasts about 2 months.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China